DiscoveRx Launches Beta-Arrestin Assay Platform for High Throughput GPCR Screening.FREMONT, Calif. -- DiscoveRx Corporation today announced the launch of their PathHunter(TM) Beta-Arrestin assay, a universal G-protein coupled receptor (GPCR GPCR Guanine Nucleotide-Binding Protein-Coupled Receptor GPCR GTP-binding Protein-Coupled Receptor ) screening platform that utilizes a proprietary ProLink(TM) tag along tag along Verb to accompany someone, esp. when uninvited: I tagged along behind the gang Verb 1. with the well established enzyme fragment complementation Complementation (genetics) The complementary action of different genetic factors. The term usually implies two homologous chromosomes or chromosome sets, each defective because of mutation and unable by itself to promote the normal development or metabolism of (EFC EFC Expected Family Contribution EFC Expect(ed) Further Clearance EFC Evangelical Fellowship of Canada EFC Evangelical Free Church EFC Eastfield College EFC Everton Football Club EFC Electronic Fee Collection ) technology. This launch further strengthens DiscoveRx leadership position as a provider of GPCR assays. Commenting on the launch Dr. Pyare Khanna, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of DiscoveRx said, "The PathHunter Beta-Arrestin assay is another revolutionary offering from DiscoveRx which further confirms our commitment to provide novel, chemiluminescent chem·i·lu·mi·nes·cence n. Emission of light as a result of a chemical reaction at environmental temperatures. chem assays for both biochemical and cell based drug discovery research and screening. This product was developed in response to a market demand for a non-imaging, HTS HTS Heights HTS Harmonized Tariff System HTS High Throughput Screening (biomolecular assay screening) HTS High-Throughput Screening (Pharmaceutical Industry) HTS Harmonized Tariff Schedule technology for studying virtually any GPCR. With a product portfolio that includes Beta-Arrestin technology, HitHunter(TM) cAMP assays, HitHunter IP3 assays, Calcium NW and Coelenterazine reagents, DiscoveRx is the only GPCR assay provider that offers best-in-class screening solutions for every major type of GPCR target." The PathHunter cell based assay platform utilizing the ProLabel(TM) tag has proven to be an enabling system for drug discovery that provides a unique assay platform to measure protein expression, degradation, secretion and translocation translocation /trans·lo·ca·tion/ (trans?lo-ka´shun) the attachment of a fragment of one chromosome to a nonhomologous chromosome. Abbreviated t. for a variety of drug discovery target classes. With the launch of the ProLink tag and Beta-Arrestin Assay, a whole new suite of PathHunter assays that revolve around protein-protein interactions will soon be possible. DiscoveRx plans to offer the PathHunter Beta-Arrestin technology without need of any licensing arrangements. The product portfolio includes Arrestin-EA cell lines, plasmids for expressing GPCRs and screening reagents for one step, homogeneous chemiluminescent detection. Parties interested in this technology should contact their DiscoveRx technical sales representative or visit the website at www.discoverx.com. About DiscoveRx Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. DiscoveRx pioneered the use of beta-galactosidase enzyme fragment complementation in biochemical assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and our products have been adopted in pharmaceutical and biotech drug screening initiatives for a number of years. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion